Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.37 |
| ▸ | JAK2 | O60674 | 5/20 | 0.36 |
| ▸ | JAK1 | P23458 | 5/20 | 0.36 |
| ▸ | TYK2 | P29597 | 5/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | CAMK1D | Q8IU85 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | KIF18A | Q8NI77 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5401187 | 1.00 | SCN9A (0.37) | SCN9AJAK2JAK1TYK2JAK3 | |
| SCHEMBL14429009 | 0.90 | RAD52 (0.40) | SCN9ACAMK1DSMN1; SMN2RAD52RECQL | |
| SCHEMBL5384742 | 0.89 | KDR (0.40) | SCN9AJAK2JAK1TYK2CAMK1D | |
| SCHEMBL5382983 | 0.89 | TERT (0.40) | SCN9ACAMK1DTSHRSMN1; SMN2BACE1 | |
| SCHEMBL5386641 | 0.88 | PLG (0.41) | SCN9ACAMK1DTSHRSMN1; SMN2 | |
| SCHEMBL5376597 | 0.88 | PLG (0.41) | SCN9ACAMK1DTSHRSMN1; SMN2 | |
| SCHEMBL5382803 | 0.88 | SCN9A (0.36) | SCN9AJAK2JAK1TYK2JAK3 | |
| SCHEMBL5380962 | 0.87 | SCN9A (0.38) | SCN9AJAK2JAK1TYK2JAK3 | |
| SCHEMBL5383371 | 0.86 | KMT2A (0.36) | SCN9ACAMK1DTSHRSMN1; SMN2PTGS2 | |
| SCHEMBL5381117 | 0.86 | KMT2A (0.36) | SCN9ACAMK1DTSHRSMN1; SMN2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-7223759-B2 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050239827-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compouds | ANADYS PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | DDC, DPP3, AMPD3 | SCN9A 4552/4885JAK2 1863/4885JAK1 3545/4885 |
| US-20050239827-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compouds | AMPD3, AAAS, PEPD | SCN9A 4783/4885JAK2 973/4885JAK1 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.